Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lilly to proceed with late-stage development of inhaled insulin

Aug. 12, 2004

Novartis claims new PCaR antagonists for use as PTH secretion promoters

Aug. 12, 2004

New phase I study begins for GT389-255 for obesity

Aug. 12, 2004

New glucagon antagonists discovered by Novo Nordisk scientists

Aug. 11, 2004

European recommendation for extended dosing of Aranesp

Aug. 11, 2004

New phase I study of AT-1001 for Fabry's disease

Aug. 11, 2004

In vivo characterization of a rapid-acting thyroid hormone derivative

Aug. 11, 2004

Two series of NPY Y5 antagonists presented by Pfizer scientists

Aug. 10, 2004

Novel thrombopoietin mimetics under development at GSK

Aug. 10, 2004

Topline results from Opterone study

Aug. 10, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...